AxoGen (NASDAQ:AXGN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Monday, Wall Street Zen reports.
A number of other research analysts have also weighed in on AXGN. HC Wainwright lifted their price objective on shares of AxoGen from $53.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, October 29th. Barclays increased their target price on AxoGen from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, October 29th. Raymond James Financial reaffirmed an "outperform" rating and issued a $57.00 price target on shares of AxoGen in a report on Thursday, October 29th. Jefferies Financial Group reiterated a "buy" rating and issued a $60.00 price target on shares of AxoGen in a research report on Wednesday, October 28th. Finally, Canaccord Genuity Group boosted their price objective on AxoGen from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, October 29th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $57.92.
Read Our Latest Report on AxoGen
AxoGen Price Performance
AXGN opened at $55.93 on Monday. The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of -86.05 and a beta of 1.21. The company has a quick ratio of 10.67, a current ratio of 12.02 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $43.27 and a 200-day moving average price of $40.44. AxoGen has a twelve month low of $23.00 and a twelve month high of $59.72.
AxoGen (NASDAQ:AXGN - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.08. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.45 million. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. Equities analysts expect that AxoGen will post -0.36 EPS for the current year.
Insider Buying and Selling
In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the transaction, the director directly owned 10,650 shares of the company's stock, valued at $529,305. This trade represents a 24.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is currently owned by insiders.
Institutional Investors Weigh In On AxoGen
Institutional investors and hedge funds have recently made changes to their positions in the business. Caxton Associates LLP purchased a new position in shares of AxoGen during the third quarter worth about $473,000. Stephens Investment Management Group LLC increased its position in shares of AxoGen by 336.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,130,854 shares of the medical equipment provider's stock worth $47,405,000 after purchasing an additional 871,949 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of AxoGen by 2,822.7% in the third quarter. Global Retirement Partners LLC now owns 643 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 621 shares during the last quarter. White Pine Capital LLC purchased a new stake in AxoGen in the third quarter valued at approximately $1,812,000. Finally, Russell Investments Group Ltd. raised its stake in AxoGen by 163.7% in the third quarter. Russell Investments Group Ltd. now owns 334,902 shares of the medical equipment provider's stock valued at $14,039,000 after purchasing an additional 207,916 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company's stock.
About AxoGen
(
Get Free Report)
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company's offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.